Refametinib

N/A

Report date: 2022/06/27 20:00:35
NME

Base Information

Drug NameRefametinib
Drug Alias Name瑞法替尼refametinib瑞美替尼refametinibum雷法替尼 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsPancreatic NeoplasmsCarcinoma, HepatocellularNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesValeant
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBayer Pharma AgBayer Schering Pharma Ag Spółka Akcyjna Oddział W PolsceBayer AG +[5] 
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsCarcinoma, HepatocellularNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A